Stock TRML TOURMALINE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
15.68 USD -2.00% Intraday chart for Tourmaline Bio, Inc. +1.49% -40.11%
Apr. 25 Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI
Apr. 25 Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024. CI

Evolution of the average Target Price on Tourmaline Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

67e.ospVaLw5ruwAmniG4fmtQAtTA4nBsGVFM7wboiKr10w.550mJ8l9nK9z8T7V1arVciYERdui_S93BtZez2fvmDyPhDwP613ohDbvDw~269da8d6307b9bfc2657961064084fcf

Analyst Recommendations on Tourmaline Bio, Inc.

Jefferies Starts Coverage on Tourmaline Bio with Buy Rating, $41 Price Target MT
Truist Starts Tourmaline Bio With Buy Rating, $43 Price Target MT
Piper Sandler Initiates Coverage on Tourmaline Bio with Overweight Rating, $65 Price Target MT
HC Wainwright Downgrades Talaris Therapeutics to Neutral From Buy MT
Morgan Stanley Adjusts Price Target on Talaris Therapeutics to $3 From $6, Keeps Equalweight Rating MT
HC Wainwright Adjusts Talaris Therapeutics' Price Target to $12 From $18, Maintains Buy Rating MT
SVB Securities Lowers Talaris Therapeutics Price Target to $2 From $7, Maintains Market Perform Rating MT
HC Wainwright Starts Talaris Therapeutics at Buy With $18 Price Target MT
Morgan Stanley Cuts Price Target on Talaris Therapeutics to $6 From $8, Maintains Equalweight Rating MT
Morgan Stanley Downgrades Talaris Therapeutics to Equalweight From Overweight; Price Target is $8 MT
SVB Securities Downgrades Talaris Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $21 MT
Morgan Stanley Adjusts Talaris Therapeutics' Price Target to $20 from $21, Keeps Overweight Rating MT
Morgan Stanley Adjusts Talaris Therapeutics Price Target to $21 From $20, Maintains Overweight Rating MT
TALARIS THERAPEUTICS : SVB Leerink Starts Talaris Therapeutics at Outperform With $21 Price Target MT
TALARIS THERAPEUTICS : Evercore ISI Starts Talaris Therapeutics at Outperform With $35 Price Target MT
TALARIS THERAPEUTICS : Morgan Stanley Starts Talaris Therapeutics at Overweight With $35 Price Target MT
TALARIS THERAPEUTICS : Guggenheim Starts Talaris Therapeutics at Buy With $26 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.68 USD
Average target price
58.33 USD
Spread / Average Target
+272.02%
High Price Target
74 USD
Spread / Highest target
+371.94%
Low Price Target
48 USD
Spread / Lowest Target
+206.12%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Tourmaline Bio, Inc.

Jefferies & Co.
Truist Securities
Piper Sandler
HC Wainwright
Morgan Stanley
SVB Securities LLC
SVB Leerink
Evercore ISI
Guggenheim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TRML Stock
  4. Consensus Tourmaline Bio, Inc.